Robert Glassman, a director at $PHVS, sold 5,333 shares of the company on 05-15-2026 for an estimated $159,090. We received data on the trade from a recent SEC filing. This was a sale of approximately 26.0% of their shares of this class of stock. Following this trade, they now own 15,167 shares of this class of $PHVS stock.
$PHVS Insider Trading Activity
$PHVS insiders have traded $PHVS stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $PHVS stock by insiders over the last 6 months:
- ANNE LESAGE (Chief Early Development) has made 0 purchases and 10 sales selling 63,000 shares for an estimated $1,901,695.
- JOHANNES GERARDUS CHRISTIAAN PETRUS SCHIKAN has made 0 purchases and 5 sales selling 40,000 shares for an estimated $1,209,926.
- PENG LU (Chief Medical Officer) has made 0 purchases and 6 sales selling 40,000 shares for an estimated $1,206,682.
- BERNDT MODIG (Chief Executive Officer) has made 0 purchases and 3 sales selling 25,625 shares for an estimated $712,839.
- WIM SOUVERIJNS (Chief Commercial Officer) sold 10,000 shares for an estimated $299,163
- ROBERT GLASSMAN has made 0 purchases and 2 sales selling 10,000 shares for an estimated $298,245.
- STEFAN ANDREAS ABELE (Chief Technical Ops Officer) sold 8,748 shares for an estimated $260,864
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PHVS Hedge Fund Activity
We have seen 43 institutional investors add shares of $PHVS stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,835,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $50,934,958
- DEERFIELD MANAGEMENT COMPANY, L.P. added 683,578 shares (+28.0%) to their portfolio in Q4 2025, for an estimated $18,969,289
- VR ADVISER, LLC removed 674,599 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,720,122
- POLAR CAPITAL HOLDINGS PLC added 543,054 shares (+228.2%) to their portfolio in Q1 2026, for an estimated $15,341,275
- OCTAGON CAPITAL ADVISORS LP removed 506,465 shares (-75.4%) from their portfolio in Q1 2026, for an estimated $14,307,636
- PRICE T ROWE ASSOCIATES INC /MD/ removed 499,349 shares (-53.0%) from their portfolio in Q1 2026, for an estimated $14,106,609
- POINT72 ASSET MANAGEMENT, L.P. added 295,391 shares (+41.5%) to their portfolio in Q1 2026, for an estimated $8,344,795
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PHVS Analyst Ratings
Wall Street analysts have issued reports on $PHVS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 12/04/2025
To track analyst ratings and price targets for $PHVS, check out Quiver Quantitative's $PHVS forecast page.
$PHVS Price Targets
Multiple analysts have issued price targets for $PHVS recently. We have seen 9 analysts offer price targets for $PHVS in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $74.0 on 05/13/2026
- Andy Chen from Wolfe Research set a target price of $42.0 on 04/09/2026
- Laura Chico from Wedbush set a target price of $42.0 on 04/07/2026
- Brian Abrahams from RBC Capital set a target price of $51.0 on 04/06/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $60.0 on 03/03/2026
- Tazeen Ahmad from B of A Securities set a target price of $30.0 on 12/04/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $39.0 on 12/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
